Inventor · disambiguated record
Raj K. Puri
Also filed as: PURI RAJ · PURI RAJ K
14 granted patents·14 pending applications·558 citations·filing 1994–2022
93Inventor score
Files withUS HEALTH12MEDICENNA THERAPEUTICS INC4MESHABERASE LLC3US GOV HEALTH & HUMAN SERV2NEOPHARM INC1
Top patents by PatentIndex Score
28 records- 0193US6011002ACircularly permuted ligands and circularly permuted chimeric moleculesUS HEALTH·Filed 1995·Granted Jan 4, 2000·116 cites·50 claims
- 0293US5614191AIL-13 receptor specific chimeric proteins and uses thereofUS HEALTH·Filed 1995·Granted Mar 25, 1997·118 cites·21 claims
- 0390US9629899B2Targeted cargo protein combination therapyTHE UNITED STATES OF AMERICA DEPT OF HEALTH AND HUMAN SERVICES·Filed 2015·Granted Apr 25, 2017·8 cites·4 claims
- 0488US5919456AIL-13 receptor specific chimeric proteinsUS HEALTH·Filed 1997·Granted Jul 6, 1999·70 cites·14 claims
- 0588US5635599AFusion proteins comprising circularly permuted ligandsUS HEALTH·Filed 1994·Granted Jun 3, 1997·72 cites·17 claims
- 0686US6518061B1IL-13 receptor specific chimeric proteins and uses thereofUS HEALTH·Filed 1996·Granted Feb 11, 2003·78 cites·12 claims
- 0786US6428788B1Compositions and methods for specifically targeting tumorsPENN STATE UNIVERSITY·Filed 1996·Granted Aug 6, 2002·85 cites·53 claims
- 0882US11084856B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2018·Granted Aug 10, 2021·1 cites·12 claims
- 0979US12503496B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2022·Granted Dec 23, 2025·0 cites·12 claims
- 1077US10849960B2Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancerUS HEALTH·Filed 2018·Granted Dec 1, 2020·1 cites·17 claims
- 1175US7541040B2Chimeric molecule for the treatment of th2-like cytokine mediated disordersUS HEALTH·Filed 2002·Granted Jun 2, 2009·9 cites·18 claims
- 1274US2010183545A1Targeted cargo protein combination therapyUS OF AMERICA AS REPRESENTED B·Filed 2009·Application pending·0 cites
- 1373US2022048965A1Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1471US11052057B2Use of cysteamine and derivatives thereof to suppress tumor metastasesMESHABERASE LLC·Filed 2019·Granted Jul 6, 2021·0 cites·20 claims
- 1570US11352402B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2018·Granted Jun 7, 2022·0 cites·16 claims
- 1669US2010104507A1Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivoUS GOV HEALTH & HUMAN SERV·Filed 2009·Application pending·0 cites
- 1767US2013331334A1Targeted cargo protein combination therapyUS HEALTH·Filed 2013·Application pending·0 cites
- 1866US2019142769A1Use of cysteamine and derivatives thereof to suppress tumor metastasesMESHABERASE LLC·Filed 2019·Application pending·0 cites
- 1966US2014314841A1Use of Cysteamine and Derivatives Thereof to Suppress Tumor MetastasesUS HEALTH·Filed 2014·Application pending·0 cites
- 2065US2017202922A1Targeted cargo protein combination therapyPURI RAJ K·Filed 2017·Application pending·0 cites
- 2161US2018042870A1Use of cysteamine and derivatives thereof to suppress tumor metastasesMESHABERASE LLC·Filed 2017·Application pending·0 cites
- 2259US2016184242A1Use of Cysteamine and Derivatives Thereof to Suppress Tumor MetastasesUS HEALTH·Filed 2016·Application pending·0 cites
- 2356US2024189351A1Il-13ra2 chimeric antigen receptors and methods of useUS HEALTH·Filed 2022·Application pending·0 cites
- 2456US2024239857A1Il-13ralpha2 targeted immunotoxins and methods of useUS HEALTH·Filed 2022·Application pending·0 cites
- 2550US2003129132A1IL-13 receptor specific chimeric proteins & uses thereofUS GOV HEALTH & HUMAN SERV·Filed 2002·Application pending·0 cites
- 2647US2004136959A1Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il -13 receptor alpha chainFiled 2001·Application pending·0 cites
- 2746US2005002918A1Selective treatment of IL-13 expressing tumorsNEOPHARM INC·Filed 2004·Application pending·0 cites
- 2837US9072716B2Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cellsSTROBER WARREN·Filed 2006·Granted Jul 7, 2015·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Raj K. Puri files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →